drugset / Trial / NCT00586625

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

NCT00586625

Phase 3 Completed 861 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety study for bepotastine besilate ophthalmic solution in normal volunteers

Timeline

Start
2007-10
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepotastine Small molecule 1.5 % Topical

Indications